Study Metrics
Total Sample
716
Treatment Group
244
Control Group
472
PICO Comparisons
1
Quality Indicators
Transparency
High
DAG Usage
Yes
QBA Performed
No
Study Information
| First Author: | Goriacko |
| Publication Year: | 2024 |
| DOI: | https://doi.org/10.1093/ajhp/zxae161 |
| Preprint: | No preprint |
Institution & Funding
| Institution Type: | Academic |
| Institutions: | Montefiore Medical Center, Albert Einstein College of Medicine, Carolinas Medical Center |
| Funding: | Declared: Public |
| Funding Institutions: | Financial support for this study was provided in part by a grant from the Agency for Healthcare Research and Quality (K12HS026396). The funder had no role in designing the study, interpreting the data, or writing or publishing the report. |
Study Context
| Disease: | COVID-19 |
| Disease Category: | Infectious diseases |
| Data Type: | Electronic Health Records |
| Number of Data Sources: | 1 |
| Geography: | US |
| Eligible Sample: | 3293.0 |
| Number of Emulations: | 2 |
| Number of Treatments: | 2 |
Analytical Methods
| Matching Method: | Coarsened exact matching |
| Analysis Method: | Logistic regression |
| Estimand: | ITT, PP |
Quality Methods
Directed Acyclic Graph (DAG)
Used
Quantitative Bias Analysis (QBA)
Not Performed
Good Practice: This study employed advanced methodological approaches
including DAG methodology.
Target Trial Information
| Target Trial Name: | REMAP-CAP |
| Registration Number: | NCT02735707 |
| Target Trial DOI: | https://doi.org/10.1056/NEJMoa2100433 |
TTE vs RCT Comparisons
Detailed comparison between Target Trial Emulation results and corresponding Randomized Controlled Trial outcomes.
28-day all-cause mortality
REMAP-CAP
OR
Efficacy
Population
Critically ill patients with COVID-19
Intervention
tocilizumab
Comparison
no tocilizumab
Outcome
28-day all-cause mortality
RCT Result
0.76
95% CI: [0.66, 0.88]
vs
TTE Result
0.86
95% CI: [0.52, 1.44]
Concordance Assessment
Confidence Interval Overlap:
Yes
CIs overlap, suggesting concordance
CIs overlap, suggesting concordance
Direction Agreement:
Same Direction
Both point to similar conclusion
Both point to similar conclusion
Transparency Indicators
Protocol Registration
Available
Data Sharing
Not Available
Code Sharing
Not Available
Overall Transparency Score:
High Transparency - This study meets good transparency standards.
Conflicts & Funding
| Conflicts of Interest: | Declared: None |
| Funding Source: | Declared: Public |
| Funding Institutions: | Financial support for this study was provided in part by a grant from the Agency for Healthcare Research and Quality (K12HS026396). The funder had no role in designing the study, interpreting the data, or writing or publishing the report. |